
Advancing SUD Treatment: DEA’s Final Rule on OUD Treatment
The landscape of medication‑assisted treatment (MAT) has shifted dramatically over the past few years. ABHW has long advocated for policies that expand access to evidence-based treatment for opioid use disorder (OUD), including supporting and advancing the Mainstream Addiction Treatment (MAT) Act, which eliminated the burdensome Data waiver (X Waiver) requirement in 2022. Following the passage of the MAT Act, and Congress’s expansion of training requirements for controlled‑substance prescribers, the U.S. Drug Enforcement Administration (DEA) has now finalized the regulatory updates needed to bring federal rules in line with these reforms.
























